Medicamen Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Medicamen Biotech has a total shareholder equity of ₹2.2B and total debt of ₹201.7M, which brings its debt-to-equity ratio to 9.3%. Its total assets and total liabilities are ₹2.9B and ₹726.0M respectively. Medicamen Biotech's EBIT is ₹115.6M making its interest coverage ratio 3.3. It has cash and short-term investments of ₹64.2M.
Key information
9.3%
Debt to equity ratio
₹201.68m
Debt
| Interest coverage ratio | 3.3x |
| Cash | ₹64.15m |
| Equity | ₹2.16b |
| Total liabilities | ₹725.97m |
| Total assets | ₹2.89b |
Recent financial health updates
Recent updates
What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 27% Share Price Gain Is Not Telling You
Dec 17
Medicamen Biotech Limited's (NSE:MEDICAMEQ) P/S Is Still On The Mark Following 41% Share Price Bounce
Sep 28Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00
Sep 03Medicamen Biotech (NSE:MEDICAMEQ) Is Due To Pay A Dividend Of ₹1.00
Aug 16These 4 Measures Indicate That Medicamen Biotech (NSE:MEDICAMEQ) Is Using Debt Extensively
Jul 04What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 28% Share Price Gain Is Not Telling You
May 21More Unpleasant Surprises Could Be In Store For Medicamen Biotech Limited's (NSE:MEDICAMEQ) Shares After Tumbling 26%
Mar 17Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00
Sep 13Why Medicamen Biotech's (NSE:MEDICAMEQ) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 19There's Reason For Concern Over Medicamen Biotech Limited's (NSE:MEDICAMEQ) Price
Dec 03Financial Position Analysis
Short Term Liabilities: MEDICAMEQ's short term assets (₹1.6B) exceed its short term liabilities (₹688.0M).
Long Term Liabilities: MEDICAMEQ's short term assets (₹1.6B) exceed its long term liabilities (₹38.0M).
Debt to Equity History and Analysis
Debt Level: MEDICAMEQ's net debt to equity ratio (6.4%) is considered satisfactory.
Reducing Debt: MEDICAMEQ's debt to equity ratio has increased from 4.5% to 9.3% over the past 5 years.
Debt Coverage: MEDICAMEQ's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: MEDICAMEQ's interest payments on its debt are well covered by EBIT (3.3x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/17 23:44 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medicamen Biotech Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |